279 The phase 3 HELIOS-B trial (NCT04153149), a multicenter, double-blind, randomized controlled trial, recently reported that vutrisiran reduced the primary endpoint, a composite of all-cause mortality and recurrent cardiovascular events, by 28% in the overall population and by 33% in the monotherapy subgroup
The emails I was getting from Christine, Head of Nutrition at Beyond Body, were almost exactly the same as the emails I had gotten from Christine, the Head of Nutrition at Colon Broom, when I took their quiz in order to do a Reel about that product
Gastrin is a neuroendocrine peptide, which acts on the cholecystokinin-2 (CCK2) receptor and is expressed in the pancreas with the rationale being that as it is involved in pancreas development, it might increase -cell mass and glycemic control [70]
As mentioned, GLP-1RAs can reduce the content of systemic inflammation markers